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Xiaoming Yao and Alan S. Verkman*Abstract
Neuromyelitis optica spectrum disorders (herein called NMO) is an inflammatory demyelinating disease of the central
nervous system in which pathogenesis involves complement-dependent cytotoxicity (CDC) produced by
immunoglobulin G autoantibodies targeting aquaporin-4 (AQP4-IgG) on astrocytes. We reported evidence previously,
using CD59−/− mice, that the membrane-associated complement inhibitor CD59 modulates CDC in NMO (Zhang and
Verkman, J. Autoimmun. 53:67–77, 2014). Motivated by the observation that rats, unlike mice, have human-like
complement activity, here we generated CD59−/− rats to investigate the role of CD59 in NMO and to create NMO
pathology by passive transfer of AQP4-IgG under conditions in which minimal pathology is produced in normal rats.
CD59−/− rats generated by CRISPR/Cas9 technology showed no overt phenotype at baseline except for mild hemolysis.
CDC assays in astrocyte cultures and cerebellar slices from CD59−/− rats showed much greater sensitivity to AQP4-IgG
and complement than those from CD59+/+ rats. Intracerebral administration of AQP4-IgG in CD59−/− rats produced
marked NMO pathology, with astrocytopathy, inflammation, deposition of activated complement, and demyelination,
whereas identically treated CD59+/+ rats showed minimal pathology. A single, intracisternal injection of AQP4-IgG in
CD59−/− rats produced hindlimb paralysis by 3 days, with inflammation and deposition of activated complement in
spinal cord, optic nerves and brain periventricular and surface matter, with most marked astrocyte injury in cervical
spinal cord. These results implicate an important role of CD59 in modulating NMO pathology in rats and demonstrate
amplification of AQP4-IgG-induced NMO disease with CD59 knockout.
Keywords: NMO, Aquaporin-4, Complement inhibitor, Astrocyte, Complement-dependent cytotoxicity, Transgenic ratIntroduction
Neuromyelitis optica spectrum disorders (herein called
NMO) is an inflammatory demyelinating disease of the
central nervous system with characteristic pathological
features in spinal cord and optic nerves, and to a lesser
extent in brain. Most NMO patients are seropositive for
immunoglobulin G autoantibodies against astrocyte
water channel aquaporin-4 (AQP4), called AQP4-IgG
(or NMO-IgG) [13, 14]. The major pathological features
in seropositive NMO include astrocyte damage, inflam-
mation with prominent granulocyte and macrophage* Correspondence: Alan.Verkman@ucsf.edu; http://www.ucsf.edu/verklab
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(http://creativecommons.org/publicdomain/zeinfiltration, vasculocentric deposition of activated com-
plement, and demyelination, which can produce marked
neurological deficits [10, 19, 26]. There is abundant evi-
dence that pathogenesis in AQP4-IgG seropositive
NMO patients involves AQP4-IgG binding to AQP4 on
astrocytes and activation of the classical complement
system, which causes complement-dependent cytotox-
icity (CDC) leading to inflammation, blood–brain barrier
disruption and demyelination [8, 13, 19]. Antibody-
dependent cell-mediated cytotoxicity (ADCC) [24] and
sensitized T cells [22, 35, 36] may also play a role in
NMO pathogenesis.
Several lines of evidence implicate a major role for
complement activation in NMO, including humanle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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[16, 18, 26], rodent models showing complement-
dependent NMO pathology following passive transfer of
AQP4-IgG [1, 28, 37], and an open-label clinical trial of
the C5 convertase inhibitor eculizumab showing efficacy
in NMO [21]. We previously reported that complement
inhibitor protein CD59, a phosphoinositol-linked mem-
brane glycoprotein expressed on astrocytes that inhibits
formation of the terminal membrane attack complex,
may be an important regulator of complement action in
NMO [38]. CD59−/− mice are highly sensitive to admin-
istration of AQP4-IgG and human complement, with
longitudinally extensive NMO spinal cord pathology
produced by coinjection of AQP4-IgG and complement
into the lumbosacral cerebrospinal space. However, a
major limitation of mice as models of NMO is the near-
zero activity of their classical complement pathway, in
part because of complement inhibitory factor(s) present
in mouse serum [25]. The ineffective classical comple-
ment pathway in mice precludes the development of
clinically relevant NMO models, such as robust passive-
transfer models of NMO optic neuritis and transverse
myelitis, as well as testing of NMO therapeutics such as
complement inhibitors.
To overcome these limitations and to further investi-
gate the role of CD59 in NMO pathogenesis, here we
generated CD59−/− rats and determined their sensitivity
to passive transfer of AQP-IgG. We previously showed
that passive transfer of AQP4-IgG to rats, without added
complement, by a single intracerebral injection produced
NMO pathology in brain at the site of injection [1]. We
tested here the prediction that marked NMO pathology
might be produced in the central nervous system by pas-
sive transfer of AQP4-IgG to CD59−/− rats, without
added complement, under conditions where minimal
pathology is produced in CD59+/+ rats.
Materials and methods
CD59−/− rats
CD59−/− rats in a Sprague–Dawley background were
custom-generated by Transposagen Biopharm. Inc.
(Lexingtobon, KY) using CRISPR-Cas9 gene targeting
technology. Exon 3 of the CD59 gene was targeted to in-
duce sequence deletions with frame-shifts, which were
identified by PCR genotyping and sequence analysis.
Primers for PCR genotyping were: CD59-11 F (5′ to 3′:
GGTCGA AGACATTTCTGGTTTAC) and CD59-11R (5′
to 3′: GACACAACAGCAGCCATTAC), followed by re-
striction enzyme digestion with HpyCH4V (Fig. 1a), which
produced distinct bands corresponding to the wildtype and
edited alleles (Fig. 1b). Breeding of CD59+/− rats was done
to generate wildtype (CD59+/+) and CD59−/− rats for exper-
iments. In vivo studies were done on 8- to 10-week-old,
weight-matched CD59+/+ and CD59−/− rats. Rats weremaintained in air-filtered cages and fed normal rat chow in
the University of California, San Francisco (UCSF) Animal
Care facility. All procedures were approved by the UCSF
Committee on Animal Research.
Materials
Purified recombinant AQP4-IgG (rAb-53) was provided
by Dr. Jeffrey Bennett (Univ. Colorado, Denver). Human
complement was purchased from Innovative Research
(Novi, MI) and human control IgG from Pierce Biotech-
nology (Rockford, IL). Unless otherwise specified chemi-
cals were purchased from Sigma-Aldrich (St. Louis, MO).
Astrocyte cell culture
Primary astrocyte cultures were generated from brain
cortex of neonatal CD59+/+ and CD59−/− rats at day 7
post birth, as described [15] with modification. Briefly,
the cerebral hemispheres were isolated and cortical tis-
sue was minced and incubated for 15 min at 37 °C in
0.25% trypsin-EDTA. Dissociated cells were centrifuged
and resuspended in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% FBS and 1% penicillin/strepto-
mycin, and grown at 37 °C in a 5% CO2 incubator. After
cell confluence (8–10 days), flasks were shaken in a rota-
tor at 180 rpm overnight to purify astrocytes and
medium was replaced with DMEM containing 3% FBS
and 0.25 mM dibutyryl cAMP. Cultures were maintained
for an additional 2 weeks. Cultures contained >95% as-
trocytes as shown by positive glial fibrillary acidic pro-
tein (GFAP) immunofluorescence.
Complement-dependent cytotoxicity (CDC)
Astrocyte cultures were trypsinized and plated onto 96-
well microplates at 20,000 cells/well and grown for 48 h.
Human complement and AQP4-IgG were added in
Hank’s balanced salt solution (HBSS, pH 7.2; Invitrogen),
and cells were incubated at 28 °C for 2 h for cytotoxicity
measurement by the Alamar Blue assay (Invitrogen) as
described [38].
Organotypic cerebellar slice cultures and ex vivo NMO
model
Cerebellar slice cultures were prepared using an interface-
culture method as described [34] with modification. Post-
natal day 7 CD59+/+ and CD59−/− rats were decapitated
and the whole cerebellum was removed, placed in ice-cold
HBSS and embedded in 2% low-melting point agarose.
Parasagittal slices of 300-μm thickness were cut using
a vibrating microtome and placed on transparent,
non-coated membrane inserts (Millipore, Millicell-CM
0.4-μm pores, 30-mm diameter) in six-well plates
containing 1 mL culture medium (50% MEM, 25%
HBSS, 25% horse serum, 1% penicillin-streptomycin,
0.65% glucose and 25 mM HEPES), with a thin film
Fig. 1 Generation and characterization of CD59−/− rats. a. Schematic of CD59 gene deletion strategy showing deletion of 11 bp in exon 3, and
PCR genotyping strategy. b. PCR genotype analysis following HpyCH4V restriction enzyme digestion, showing a single band at 269 bp for
CD59−/− rats, two bands at 182 bp and 98 bp for CD59+/+ rats, and three bands for CD59+/− rats. c. Growth curves of CD59+/+, CD59+/−
and CD59−/− rats (20 rats per group, differences not significant). d. Genotype distribution of 150 pups from breeding of CD59+/− rats. e. (left) CD59
immunofluorescence in blood smears. (right) Percentage erythrocyte lysis following complement activation (mean ± S.E.M., n = 6, **P < 0.01)
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tured in 5% CO2 at 37 °C for 7 days with medium
change every 2 days. AQP4-IgG (or control human
IgG) and human complement were added on day 7
and slices were fixed 24 h later in 4% paraformalde-
hyde (PFA) for whole-mount immunostaining.Blood analysis
Blood (200 μL) was collected into EDTA tubes for cell
analysis and into tubes without anticoagulant for serum.
To study complement-mediated erythrocyte lysis,
100 μL of fresh rat serum was placed in wells of a 96-
well plate and acidified by addition of 10 μL of 0.2 N
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[23]. Erythrocytes (10 μL of 50% suspension in PBS)
were added to each well, and hemolysis quantified by ab-
sorbance at 412 nm after 1 h incubation at 37 °C, refer-
enced against zero and 100% lysis controls. Hematology
parameters were measured using a Genesis Hematology
Analyzer (Oxford Science, Oxford, CT).
Intracerebral injection model
AQP4-IgG (30 μg) was delivered by intracerebral injec-
tion as described [1] with modification. CD59+/+ and
CD59−/− rats were anesthetized with ketamine (100 mg/
kg) and xylazine (10 mg/kg) and mounted on a stereo-
taxic frame. A midline scalp incision was made and a
burr hole of 1-mm diameter was drilled on each side of
the skull 0.5 mm anterior and 3.5 mm lateral to the
bregma. A glass pipette with 40-μm diameter tip was
inserted at a depth of 5 mm to infuse AQP4-IgG (or
control IgG) in a total volume of 3 μL over 10 min by
pressure injection. After injection, the glass pipette was
kept in place for 10 min before slow withdrawal (over
5 min) to prevent leaking. At day 7 rats were deeply
anesthetized and transcardially perfused with 200 mL
heparinized PBS and 200 mL of 4% PFA in PBS. Brains
were removed and post-fixed for 4 h in 4% PFA and cry-
toprotected in 20% sucrose. Serial frozen coronal sec-
tions (thickness 7 μm) were cut on a cryostat.
Intracisternal injection model
AQP4-IgG was delivered by injection into the cisterna
magna of CD59+/+ and CD59−/− rats. Rats were anesthe-
tized as above, mounted on a stereotaxic frame, the
cisterna magna was exposed, and a glass pipette with 40-
μm tip diameter was inserted. AQP4-IgG or control IgG
(15 or 30 μg in 10 μL artificial cerebrospinal fluid, aCSF)
was infused at 2 μl/min over 5 min by pressure injection
at 10 psi. In some experiments a recombinant monoclo-
nal anti-AQP4 ‘aquaporumab’ lacking effector functions
(AQP4-IgG-CDC) [30] was infused. After injection, the
glass pipette was withdrawn with no leakage seen. At
specified times, rats were euthanized as above, and
brain, spinal cord and optic nerves were removed for
sectioning. Rat motor function was scored as described
[20] with modification: score 0 = normal movement;
score 1, tail paralysis; score 2, hindlimb paralysis; score
3, hindlimb paralysis with frontlimb paresis; score 4,
complete paralysis with moribund condition.
Immunofluorescence
Cultured astrocytes and cerebellar slice cultures were
fixed with 4% PFA for 15 min and incubated in blocking
solution as described [34]. Frozen sections of brain,
spinal cord and other organs were post-fixed with 4%
PFA for 5 min and incubated in blocking solution asdescribed [34]. Slides were then incubated for 2 h with
antibodies against GFAP (1:200; Millipore), AQP4 (1:200,
Santa Cruz Biotechnology), ionized calcium binding
adaptor molecule 1 (Iba1; 1:400, Wako, Richmond, VA),
CD45 (1:20, Cambridge, MA), C9neo (1:100, Santa Cruz
Biotechnology), myelin basic protein (MBP, 1:100, Santa
Cruz Biotechnology), human IgG (1:100, Santa Cruz Bio-
technology), or CD59 (7A6, 5 μg/mL, LSBio, Seattle, WA),
followed by the appropriate species-specific Alexa Fluor-
conjugated secondary antibody for 1 h (5 μg/mL each,
Invitrogen). Sections were mounted with VectaShield
(Vector Laboratories, Burlingame, CA) for visualization of
immunofluorescence on a Leica fluorescence microscope
or Nikon confocal microscope.
Statistics
Data are presented as mean ± S.E.M. Statistical analysis
was performed using Prism 5 GraphPad Software pack-
age (San Diego, CA). The normality of the data was
established by Bartlett’s test for equal variances and a
one-way ANOVA with Newmann-Keuls post-hoc test to
compare groups.
Results
Generation and characterization of CD59−/− rats
CD59−/− rats were generated as diagrammed in Fig. 1a.
Following breeding and attempted expansion of 3 rat
clones, we selected a clone that thrived well, which con-
tained an 11-bp deletion in exon 3 of the rat CD59 gene.
Genomic PCR analysis following restriction enzyme di-
gestion of PCR products showed CD59+/+, CD59+/− and
CD59−/− rats from breeding of CD59+/− rats (Fig. 1b).
CD59−/− rats showed no overt phenotype, including
neurological function and behavior, with similar growth
found for CD59−/− and CD59+/+ rats (Fig. 1c), and
breeding of CD59+/− rats gave an approximate 1:2:1 dis-
tribution of viable CD59+/−, CD59+/− and CD59−/− off-
spring (Fig. 1d). CD59 immunofluorescence in multiple
tissues (blood smear shown in Fig. 1e, left) confirmed un-
detectable CD59 protein in the CD59−/− rats. Functional
studies of complement-mediated erythrocyte lysis con-
firmed the expected greater lysis in CD59−/− compared to
CD59+/+ erythrocytes (Fig. 1e, right). Hematological pa-
rameters suggested a mild hemolytic anemia in CD59−/−
rats as evidenced by reduced hematocrit and mild reticu-
locytosis (Table 1), as has been reported in humans lack-
ing CD59 [12]. Peripheral tissues did not show
inflammation, deposition of activated complement (C5b-9
immunofluorescence), or histological abnormalities (see
below, and data not shown).
We note an interesting observation made in carrying
out control studies (of AQP4-IgG administration to
CD59−/− rats) in which complement was inactivated by
administration of cobra venom factor (350 units/kg), as
Table 1 Hematological parameters in CD59−/− and CD59+/+ rats
Hb (g/dl) RBC (1012/L) HCT (%) RDW (%) Retic (%) WBC (109/L) Plt (109/L)
CD59+/+ 14.8 ± 0.5 8.7 ± 0.4 40.3 ± 1.5 13.3 ± 2.3 2 ± 0.1 7.5 ± 2.5 737 ± 165
CD59−/− 14.3 ± 0.2* 7.8 ± 0.2* 38.5 ± 1.2* 14.2 ± 2* 12 ± 0.1* 7.4 ± 3.1 729 ± 188
Abbreviations: Hb hemoglobin, RBC red blood cell count, HCT hematocrit, RDW RBC distribution width, Retic reticulocyte count, WBC white blood cell count, Plts
platelet count
Mean ± S.D. of 6 rats per genotype (three males and three females)
*P <0.01 comparing CD59−/− with CD59+/+
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CD59−/− rats receiving cobra venom factor became
moribund and died within 12–24 h, whereas no abnor-
malities were seen in CD59+/+ rats treated identically.
Immunofluorescence of CD59 and AQP4 in CD59+/+
rats showed their gross coexpression in brain, spinal
cord and optic nerve (Fig. 2a-c), in agreement with prior
results [38]. We did not carry out high-resolution ana-
lysis of their cellular or subcellular localization. CD59
immunofluorescence of two major peripheral tissues in
which AQP4 is expressed, kidney and skeletal muscle,
also showed CD59 and AQP4 coexpression (Fig. 2d).
CD59 immunofluorescence was not seen in CNS or
peripheral tissues from CD59−/− rats, and AQP4 im-
munofluorescence was similar in tissues from CD59+/+
and CD59−/− rats.Marked complement-mediated injury in astrocyte cultures
and brain slices from CD59−/− rats
Complement-dependent cytotoxicity (CDC) was mea-
sured in primary astrocyte cultures generated from neo-
natal CD59+/+ and CD59−/− rats. Immunofluorescence
of astrocytes cultures from CD59+/+ rats showed CD59
coexpression with AQP4; similar AQP4 expression but
without CD59 was seen on astrocytes from CD59−/− rats
(Fig. 3a). CDC was measured following 2-h incubation
of astrocyte cultures with different concentrations of
AQP4-IgG in the presence of human complement
(Fig. 3b). CD59−/− astrocyte cultures were significantly
more sensitive to AQP4-IgG-induced CDC than were
CD59+/+ astrocyte cultures, similar to prior results in
CD59+/+ and CD59−/− mouse astrocyte cultures [38].
To confirm the predicted greater sensitivity of a CD59−/−
CNS tissue to development of complement-mediated
NMO-like pathology, ex vivo cultured cerebellar slices from
CD59+/+ and CD59−/− rats were incubated with AQP4-IgG
and complement for 1 day. CD59−/− cerebellar slices
showed astrocyte injury with loss of AQP4 and GFAP
immunofluorescence, seen most prominently at the periph-
eral border, and deposition of activated complement as seen
by C5b-9 immunofluorescence (Fig. 3c). In contract,
minimal loss of AQP4 and GFAP, and complement depos-
ition were seen in CD59+/+ cerebellar slices under the same
experimental conditions.Marked NMO pathology in brains of CD59−/− rats
following intracerebral AQP4-IgG injection
Direct intracerebral injection of AQP4-IgG (without
added complement) in rat brain has been shown to
produce NMO-like pathology around the injection site,
with loss of AQP4 and GFAP, deposition of activated
complement, inflammation and demyelination [1]. To
compare the sensitivity of CD59+/+ and CD59−/− rats in
this model, a submaximal amount of AQP4-IgG was
injected into brain striatum (Fig. 4a). Under conditions
in which minimal pathology was seen in CD59+/+ rats,
there was marked astrocyte injury in the ipsilateral
hemispheres of CD59−/− rats as seen by loss of AQP4
and GFAP immunofluorescence and demyelination as
seen by loss of MBP immunofluorescence (Fig. 4b), as
well as microglia activation (Iba-1 immunofluorescence),
leukocyte infiltration (CD45 immunofluorescence), and
deposition of activated complement (C5b-9 immuno-
fluorescence). Figure 4c summarizes areas of loss of
AQP4, GFAP and MBP immunofluorescence in the ipsi-
lateral, AQP4-IgG injected hemisphere and the contralat-
eral, control IgG injected hemisphere. We conclude that
CD59−/− rat brain is highly susceptible to development of
NMO pathology following exposure to AQP4-IgG.
NMO pathology in CNS tissues of CD59−/− rats following
intracisternal AQP4-IgG injection
We next introduced AQP4-IgG into the CSF by intracis-
ternal injection (Fig. 5a). In an initial study, injection of
30 μg AQP4-IgG into the CSF of CD59−/− rats produced
marked paralysis by day 1 and death soon thereafter. In
subsequent studies, intracisternal injection of a reduced,
15 μg amount of AQP4-IgG produced motor dysfunc-
tion in all CD59−/− rats by day 1, but with >80% survival
on day 3; no hindlimb motor dysfunction or mortality
was seen in CD59+/+ rats administered 15 μg AQP4-IgG
or in CD59+/+ or CD59−/− rats administered 15 μg con-
trol IgG or an engineered AQP4-IgG lacking comple-
ment effector function (Fig. 5b). Examination of skeletal
muscle and kidney from AQP4-IgG treated CD59−/− rats
did not show C5b-9 deposition or inflammation, and
human IgG was undetectable in the serum (data not
shown), suggesting that the gross motor dysfunction in
the antibody-treated CD59−/− rats is not a consequence
of peripheral organ injury.
Fig. 2 AQP4 and CD59 expression in CD59+/+ and CD59−/− rats. Immunofluorescence shown in cross-section and longitudinal section of spinal
cord (a), optic nerves (b), coronal sections of brain (c), and kidney inner medulla and skeletal muscle sarcolemma (d). Representative of two mice
per genotype
Yao and Verkman Acta Neuropathologica Communications  (2017) 5:15 Page 6 of 11Immunofluorescence of spinal cord on day 3 showed
marked loss of AQP4 and GFAP in cervical spinal cord of
AQP4-IgG-treated CD59−/− rats, with patchy and variable
loss in thoracic and lumbar spinal cord (Fig. 5c, d). Min-
imal loss of AQP4 and GFAP was seen in treated CD59+/+
rats. C5b-9 and Iba-1 immunofluorescence was seen in
cervical and thoracic spinal cord in AQP4-IgG-treatedCD59−/− rats (Fig. 5e). To investigate whether the
location-dependent pathology in spinal cord is related to
AQP4-IgG access and deposition, tissues from rats receiv-
ing 15 μg AQP4-IgG were harvested at 2 h and immuno-
stained with an anti-human secondary antibody. Figure 5f
shows detectable human IgG in cervical > thoracic spinal
cord, with little seen in lumbar spinal cord.
Fig. 3 Complement-mediated injury in CD59+/+ and CD59−/− astrocyte cultures and cerebellar slices. a. AQP4 and CD59 immunofluorescence in primary
astrocyte cultures from neonatal CD59+/+ and CD59−/− rats. b. Complement-dependent cytotoxicity in astrocyte cultures following 2-h incubation with
5% human complement and indicated concentrations of AQP4-IgG (mean ± S.E.M., n = 4, * P < 0.01). c. AQP4, GFAP and C5b-9 immunofluorescence in
cerebellar slice cultures from CD59+/+ and CD59−/− rats at 1 day after incubation with 5 μg/ml AQP4-IgG (or control-IgG) and 5% human complement.
Fluorescence micrographs shown as low and high (boxed region) magnifications. Representative of 3 sets of slice culture studies
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and variable loss of AQP4 and GFAP (results from 3 rats
per genotype shown in Fig. 6a); C5b-9 and Iba-1 im-
munofluorescence were consistently greater in the
AQP4-IgG treated CD59−/− rats than the CD59+/+ rats.
Brain sections showed patchy loss of AQP4 and GFAP,
mainly at the brain surface and in periventricular matter,
along with C5b-9 and Iba-1 immunofluorescence
(Fig. 6b). AQP4-IgG (human IgG immunofluorescence)
at 2 h after injection was not detectable in optic nerves,
but seen in a patchy distribution in brain cortex and
periventricular matter (Fig. 6c).
Discussion
Our study supports the central involvement of CD59 in
modulating complement-mediated injury in AQP4-IgG
seropositive NMO. CD59 is expressed in CNS tissues af-
fected in NMO and may play a protective role to contain
local, subclinical injury initiated by minor exposures to
AQP4-IgG. CD59−/− rats were highly sensitive to passive
transfer of AQP4-IgG by intracerebral and intracisternal
routes, without the need for added components such as
complement or pro-inflammatory factors. Though astro-
cytes may also express other complement regulator pro-
teins such as CD55, the marked effect of CD59 gene
deletion suggests that CD59 is the major complement
regulator in rat brain. As an important complement
regulator in astrocytes, drugs that enhance astrocytic
CD59 expression, perhaps identifiable by compound
screens, may be beneficial in NMO, and conversely,reduced astrocytic CD59 expression or subcellular colo-
calization with AQP4 might trigger NMO exacerbations
and worsen disease severity.
Animal models of NMO have been useful in character-
izing NMO pathogenesis mechanisms and for testing
potential NMO therapeutics. Mouse models have been
developed involving passive transfer of AQP4-IgG to-
gether with human complement by direct injections into
the brain [28] or spinal fluid [3, 35] to produce NMO-
like pathology in brain, spinal cord and optic nerve. As
mentioned in the Introduction, a fundamental limitation
of mice to study NMO is their lack of an effective clas-
sical complement activation pathway [5, 25]. Early rat
models involved administration of AQP4-IgG following
induction of experimental autoimmune encephalomyeli-
tis (EAE) [4]; however, the pathogenic mechanism in
EAE – myelin targeting by T cells – is very different
from the humoral immune response in NMO, making it
difficult to reach conclusions about NMO pathogenesis
mechanisms. We found that intracerebral injection of
AQP4-IgG produced robust NMO-like pathology in rat
brain [1], and that while systemic administration of
AQP4-IgG alone did not produce disease, NMO-like
brain pathology was seen following a small needle stab
in seropositive rats [2], which presumably allowed circu-
lating AQP4-IgG leakage into brain parenchyma to access
astrocytes, and perhaps produce a local inflammatory re-
sponse. Creation of NMO spinal cord or optic nerve path-
ology in rats has been challenging. One study involving
continuous AQP4-IgG infusion using intrathecal catheters
Fig. 4 Increased NMO pathology in CD59−/− rats following intracerebral injection of AQP4-IgG. a. Intracerebral injection model showing stereotaxic
microneedle injection of AQP4-IgG (or control IgG). b. Immunofluorescence of indicated markers in rat brain at 7 days after AQP4-IgG (or control IgG)
injection. Lesion areas indicated by white dotted boundary. c. AQP4, GFAP and MPB immunodeficient areas normalized to hemisphere areas (mean ±
S.E.M., 6 rats per genotype, **P < 0.01)
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inflammation or demyelination [9], and a similar more re-
cent study reported AQP4 loss in spinal cord and optic
nerves, as well as mildly reduction in myelin in spinal cord
[17]. The marked amplification of NMO pathology by
knockout of CD59 in rats produced astrocytopathy as well
as inflammation and deposition of activated complement.
CD59−/− rats did not manifest overt phenotypes, ex-
cept for mild reticulocytosis and reduced hemoglobin,
which is likely due to low-grade hemolysis as seen in
humans lacking CD59 [31] rather than a possible off-
target effect in genome editing that can occur using
CRISPR methods. The active classical complement sys-
tem in rats, which has similar activity to that in human
[5, 33], is presumably the reason for the low basal
hemolytic activity. As such, CD59−/− rats may be useful
to model complement-initiated diseases in various neu-
rodegenerative, hematological, renal and skeletal muscle
diseases [6, 11, 31]. Although the mechanism of high
morbidity in CD59−/− rats receiving cobra venom factor
was not established here, there appeared to be hemolysis
and organ injury, which is likely due to complementactivation and consumption by cobra venom factor,
which is the mechanism of its complement depletion ac-
tion [32, 33]. With regard to NMO, the amplified re-
sponse of CD59−/− rats to AQP4-IgG may be useful in
testing drugs that target distinct steps in the AQP4-IgG/
complement injury pathway, as well as in investigating
outstanding questions in NMO pathogenesis mecha-
nisms such as the role of sensitized T cells and the ex-
planation for the absence of significant pathology in
peripheral AQP4-expressing tissues despite their sus-
tained direct exposure to serum AQP4-IgG.
The marked NMO pathology seen in CD59−/− rats follow-
ing AQP4-IgG administration contrasts with the conclusions
of Saadoun and Papadopoulos [27], who concluded that
complement inhibitors, including CD59, are not protective
against complement injury in CNS tissues. Their findings
were based on immunofluorescence in mouse brain in
which CD59 expression was seen on astrocytes, but not at
AQP4-rich foot-processes abutting microvessels. Detection
sensitivity rather than species differences may account for
the disparate conclusions, as we previously showed marked
NMO pathology in CD59−/− mice following intracerebral or
Fig. 5 Increased NMO pathology in spinal cord of CD59−/− rats following intracisternal injection of AQP4-IgG. a. Intracisternal model showing
microneedle injection of AQP4-IgG (or control IgG). b. Neurological scores at day 3 after AQP4-IgG, control IgG, or engineered AQP4-IgG lacking
complement effector function (AQP4-IgG-CDC). Each symbol is data from a separate rat (n = 6), with mean ± S.E.M. shown (**P < 0.01). c.
Immunofluorescence of indicated markers in cervical, thoracic and lumbar spinal cord at 3 days after AQP4-IgG injection. d. Loss of AQP4
and GFAP immunofluorescence normalized to whole section area of spinal cord (mean ± S.E.M., 6 rats per genotype, **P < 0.01). e. C5b-9
and Iba-1 immunofluorescence in cervical and thoracic spinal cord at 3 days after AQP4-IgG injection. f. AQP4-IgG distribution at 2 h after
intracisternal injection visualized with an anti-human secondary antibody
Fig. 6 NMO pathology in optic nerves and brain of CD59−/− rats following intracisternal injection of AQP4-IgG. a. Immunofluorescence of indicated
markers in optic nerves at 3 days after AQP4-IgG injection. Data shown for 3 rats per genotype. b. Immunofluorescence of indicated markers near the
brain surface (‘cortex’) and around ventricles (‘peri-vent’) at 3 days after AQP4-IgG injection. c. Distribution of AQP4-IgG at 2 h after intracisternal injection
visualized with an anti-human secondary antibody
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plement [38]. Our recent development of super-resolution
microscopy methods to image AQP4 on astrocytes in fixed
CNS tissues [29] may overcome the limited resolution and
sensitivity of conventional fluorescence microscopy to detect
CD59 in subcellular regions of astrocytes. Saadoun and
Papadopoulos [27] also speculated that the absence of sig-
nificant NMO disease in peripheral AQP4-expressing tissues
such as skeletal muscle and kidney was a consequence of
CD59 and AQP4 coexpression, which should be amenable
to testing using CD59−/− rats.
Conclusion
In conclusion, our results implicate CD59 as an important
regulator in NMO pathogenesis and potentially a new
drug target with a novel mechanism of action to reduce
complement-mediated astrocyte damage, a key initiating
event in NMO. Prevention of complement-mediated
astrocyte damage by altering astrocyte susceptibility to
complement may have a more favorable side-effect profile
than by general complement inhibition.
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